Results 101 to 110 of about 1,367,754 (318)

Pseudomonas aeruginosa: the history of one of the most successful nosocomial pathogens in Russian hospitals [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2018
Pseudomonas aeruginosa is recognized as one of the six most important pathogens in terms of antimicrobial resistance («ESKAPE» pathogens), and included by WHO in the group of microorganisms for which the need for development of new antimicrobial agents ...
Skleenova E.Yu.   +5 more
doaj  

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

Quality in cancer care: nurse sensitive indicators for ambulatory chemotherapy

open access: yes, 2011
This project, commissioned by the National Cancer Action Team, developed and pilotted a suite of nurse sensitive indicators for ambulatory chemotherapy that contributed to the effective monitoring of these services.
Corner, J.   +5 more
core  

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide

open access: yes, 1996
Summary We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated
Dexter, TM   +21 more
core   +1 more source

Helping patients discuss CINV management : development of a patient charter [PDF]

open access: yes, 2013
In April 2012, an Expert Group of specialist cancer nurses working in a variety of settings (e.g. chemotherapy delivery, chemotherapy service design, research, nurse leadership and patient information/advocacy) participated in telephone/web-based ...
Dielenseger, Pascale   +10 more
core   +1 more source

Epidemiological characteristic of Streptococcus pneumoniae serotypes from patients with invasive pneumococcal disease in the Russian Federation [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия
Objective. To characterize spectrum of S. pneumoniae serotypes isolated from patients with invasive pneumococcal infection in the Russian Federation. Materials and Methods. The serotype identification of 93 S.
Muravyev A.A.   +5 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

open access: yes, 2009
Background: Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory. Pre-clinical models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune system can be mobilized to ...
Amy Prosser   +51 more
core   +1 more source

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

open access: yesNature Communications, 2019
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.
Ryohei Katayama   +23 more
doaj   +1 more source

Home - About - Disclaimer - Privacy